KR20110063457A - 대상에서의 지속적 치료 약물 농도 달성을 위한 조성물 및 방법 - Google Patents

대상에서의 지속적 치료 약물 농도 달성을 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20110063457A
KR20110063457A KR1020117005982A KR20117005982A KR20110063457A KR 20110063457 A KR20110063457 A KR 20110063457A KR 1020117005982 A KR1020117005982 A KR 1020117005982A KR 20117005982 A KR20117005982 A KR 20117005982A KR 20110063457 A KR20110063457 A KR 20110063457A
Authority
KR
South Korea
Prior art keywords
prodrug
days
administering
administration
irinotecan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117005982A
Other languages
English (en)
Korean (ko)
Inventor
마이클 에이 엘든
시바니 에스 해리트
탐라 엘 바커
Original Assignee
넥타르 테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 넥타르 테라퓨틱스 filed Critical 넥타르 테라퓨틱스
Publication of KR20110063457A publication Critical patent/KR20110063457A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117005982A 2008-09-23 2009-09-23 대상에서의 지속적 치료 약물 농도 달성을 위한 조성물 및 방법 Ceased KR20110063457A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US9951608P 2008-09-23 2008-09-23
US61/099,516 2008-09-23
US10693108P 2008-10-20 2008-10-20
US61/106,931 2008-10-20
US17343309P 2009-04-28 2009-04-28
US61/173,433 2009-04-28

Publications (1)

Publication Number Publication Date
KR20110063457A true KR20110063457A (ko) 2011-06-10

Family

ID=41268391

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117005982A Ceased KR20110063457A (ko) 2008-09-23 2009-09-23 대상에서의 지속적 치료 약물 농도 달성을 위한 조성물 및 방법

Country Status (21)

Country Link
US (3) US8906353B2 (enExample)
EP (1) EP2349346B1 (enExample)
JP (3) JP2012503602A (enExample)
KR (1) KR20110063457A (enExample)
CN (1) CN102164617A (enExample)
AU (1) AU2009297091B2 (enExample)
CA (1) CA2736939C (enExample)
CY (1) CY1122208T1 (enExample)
DK (1) DK2349346T3 (enExample)
ES (1) ES2744975T3 (enExample)
HR (1) HRP20192120T1 (enExample)
HU (1) HUE047352T2 (enExample)
IL (1) IL211888A (enExample)
LT (1) LT2349346T (enExample)
MX (1) MX2011003063A (enExample)
PL (1) PL2349346T3 (enExample)
PT (1) PT2349346T (enExample)
RS (1) RS59607B1 (enExample)
SI (1) SI2349346T1 (enExample)
SM (1) SMT201900609T1 (enExample)
WO (1) WO2010036335A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011003063A (es) 2008-09-23 2011-04-21 Nektar Therapeutics Composiciones y metodos para lograr concentraciones terapeuticas de farmaco sostenidas en un individuo.
US9359376B2 (en) * 2011-04-08 2016-06-07 Sphaera Pharma Pte. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
CN104813167B (zh) * 2012-11-28 2019-04-09 尼克塔治疗公司 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法
EP3258913A1 (en) * 2015-02-17 2017-12-27 Mallinckrodt Nuclear Medicine LLC Modified docetaxel liposome formulations and uses thereof
AU2017273495B2 (en) 2016-06-02 2023-01-12 Innopharmax, Inc. Metronomic oral gemcitabine for cancer therapy
CN106539557A (zh) * 2016-10-08 2017-03-29 西安交通大学 一种基于恒速静脉输入的药代动力学参数的测定方法
EP3852793B1 (en) 2018-09-17 2025-11-19 The Children's Hospital Of Philadelphia Macromolecular prodrug peg-[sn22]4
AU2022226605A1 (en) * 2021-02-23 2023-10-12 Edison Oncology Compositions and methods to improve the therapeutic benefit of suboptimally administered compounds and therapies for the treatment of diseases
CN115317486B (zh) * 2022-08-17 2024-04-19 南昌大学 一种共载紫杉醇和伊立替康前药纳米制剂及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4406793A (en) 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
IL117684A (en) 1995-04-07 2002-02-10 Pharmacia & Upjohn Inc Intermediates and Process for Production of History of Kempotocin (CPT-11) and Related Compounds
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
PL189698B1 (pl) 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
JP2002542304A (ja) 1999-04-28 2002-12-10 ベクトレイムド インコーポレイテッド 酵素的に活性化された重合薬物接合体
AU4564200A (en) 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
WO2001062299A2 (en) 2000-02-28 2001-08-30 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
DK1301810T3 (da) 2000-07-21 2009-01-26 Schlumberger Services Petrol Kernemagnetiske resonansfremgangsmåder til at uddrage information om et fluidum i en klippe
US20020182172A1 (en) 2000-11-30 2002-12-05 Shearwater Corporation Water-soluble polymer conjugates of triazine derivatives
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7401013B2 (en) 2001-10-15 2008-07-15 Lockheed Martin Corporation Method to optimize test data
KR20050040832A (ko) 2001-10-29 2005-05-03 넥타르 테라퓨틱스 에이엘, 코포레이션 단백질 키나아제 ｃ 억제제의 중합체 공액
DE60219677T2 (de) 2001-10-30 2008-05-15 Nektar Therapeutics Al, Corp., Huntsville Wasserlösliche polymerkonjugate von retinoesäure
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
JP2005529938A (ja) 2002-06-06 2005-10-06 ユニバーシティ オブ ワシントン 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
CN1852740B (zh) 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
EP1989212B1 (en) 2006-02-17 2013-06-19 Cascade Prodrug Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
MX2009008549A (es) 2007-02-09 2009-08-18 Enzon Pharmaceuticals Inc Tratamiento de canceres resistentes o refractarios con conjugados polimericos de brazos multiples de 7-etil-10-hidroxicamptotecina.
CN101199857B (zh) 2007-12-12 2011-04-13 中国药科大学 mPEG-PLA-喜树碱类药物的结合物
MX2011003063A (es) 2008-09-23 2011-04-21 Nektar Therapeutics Composiciones y metodos para lograr concentraciones terapeuticas de farmaco sostenidas en un individuo.

Also Published As

Publication number Publication date
JP2015034180A (ja) 2015-02-19
SMT201900609T1 (it) 2020-01-14
IL211888A0 (en) 2011-06-30
CY1122208T1 (el) 2020-11-25
MX2011003063A (es) 2011-04-21
PL2349346T3 (pl) 2020-03-31
IL211888A (en) 2015-08-31
US20150087668A1 (en) 2015-03-26
CA2736939C (en) 2021-09-14
SI2349346T1 (sl) 2019-12-31
US20180028525A1 (en) 2018-02-01
AU2009297091B2 (en) 2015-03-05
AU2009297091A1 (en) 2010-04-01
JP2012503602A (ja) 2012-02-09
PT2349346T (pt) 2019-10-24
JP2016216510A (ja) 2016-12-22
CA2736939A1 (en) 2010-04-01
DK2349346T3 (da) 2019-10-07
JP6076317B2 (ja) 2017-02-08
US8906353B2 (en) 2014-12-09
EP2349346B1 (en) 2019-08-28
US9801873B2 (en) 2017-10-31
HRP20192120T1 (hr) 2020-02-21
US20110269789A1 (en) 2011-11-03
LT2349346T (lt) 2019-09-25
CN102164617A (zh) 2011-08-24
RS59607B1 (sr) 2020-01-31
US10525051B2 (en) 2020-01-07
EP2349346A1 (en) 2011-08-03
HUE047352T2 (hu) 2020-04-28
WO2010036335A1 (en) 2010-04-01
ES2744975T3 (es) 2020-02-27

Similar Documents

Publication Publication Date Title
US10525051B2 (en) Compositions and methods for achieving sustained therapeutic drug concentrations in a subject
Zhao et al. Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy
Venditto et al. Cancer therapies utilizing the camptothecins: A review of in vivo literature
JP7703001B2 (ja) 相乗的がん治療
ES2770733T3 (es) Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas
US12514853B2 (en) Therapeutic dendrimer
EP2747761A1 (en) Methods of treating cancers with therapeutic nanoparticles
KR20160024985A (ko) 암 치료를 위한 도세탁셀 중합체성 나노입자
WO2014084378A1 (ja) 環状ｒｇｄ配列含有ペプチドを含む抗癌剤
AU2019446285B2 (en) Pharmaceutical compositions containing mixed polymeric micelles
CN102159190A (zh) 化疗剂的口服制剂
KR101678881B1 (ko) 부작용을 가지지 않는 항암제
JP2012067025A (ja) 治療活性物質の作用を増強するための高分子化環状ニトロキシドラジカル化合物の使用
HK1155083A (en) Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan)
HK1155083B (en) Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan)
AU2013205079B2 (en) Treatment of cancer
HK1161084A (en) Oral formulations of chemotherapeutic agents
HK1214145B (en) Anticancer agent having no side effects

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110315

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140826

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160112

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161124

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160112

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20161124

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160708

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20140826

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20170102

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20161216

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20161124

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160708

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160112

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20140826

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20170403

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20170102

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20161124

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20181017

Appeal identifier: 2017101001603

Request date: 20170403

J301 Trial decision

Free format text: TRIAL NUMBER: 2017101001603; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20170403

Effective date: 20181017

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20181017

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20170403

Decision date: 20181017

Appeal identifier: 2017101001603

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2018201009329; APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20181017

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190627

Appeal identifier: 2018201009329

Request date: 20181214

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2018201009329; JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20181214

Effective date: 20190627

PJ1302 Judgment (patent court)

Patent event date: 20190628

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20181214

Decision date: 20190627

Appeal identifier: 2018201009329

Appeal kind category: Appeal against decision to decline refusal